Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OIG To Study AWP Prices For Physician-Administered Drugs

Executive Summary

The HHS Office of the Inspector General will conduct studies of AWP with the aim of allowing state Medicaid programs to reimburse physician-administered drugs at a lower price
Advertisement

Related Content

Federal Upper Limit List Should Include All Eligible Drug Products, OIG Says
Federal Upper Limit List Should Include All Eligible Drug Products, OIG Says
HHS IG To Study EPO, OxyContin Reimbursement In 2004 Reports
HHS IG To Study EPO, OxyContin Reimbursement In 2004 Reports
Zyprexa Medicaid Cost Highlight Of OIG’s Mental Health Rx Spending Report
AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data
AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data
Advertisement
UsernamePublicRestriction

Register

PS042583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel